Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (371-380 of 721) with videos related to

Pageof 73
Sort By:
International Journal of Colorectal Disease|December 4, 2008
The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CTRobert Rosenberg, Ken Herrmann, Ralf Gertler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 19, 2011
Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatmentKen Herrmann, Andreas K Buck, Tibor Schuster, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2011
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinibMatthias R Benz, Ken Herrmann, Franziska Walter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 27, 2025
Multitracer comparison of gold standard PSMA-PET/CT with <sup>68</sup>Ga-FAPI and <sup>18</sup>F-FDG in high-risk prostate cancer: a proof-of-concept studyOsama Mahmoud, Lukas Püllen, Lale Umutlu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 31, 2019
<sup>18</sup>F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue SarcomasJohannes Grueneisen, Benedikt Schaarschmidt, Aydin Demircioglu, et al.
Journal for Immunotherapy of Cancer|October 19, 2023
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapyAnalena Handke, Claudia Kesch, Wolfgang Peter Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 15, 2021
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of diseaseFrancesco Barbato, Wolfgang Peter Fendler, Isabel Rauscher, et al.
Journal for Immunotherapy of Cancer|April 1, 2021
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapyJustin Ferdinandus, Martin Metzenmacher, Lukas Kessler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2022
Lesion Quantification Accuracy of Digital <sup>90</sup>Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide TherapyDavid Kersting, Walter Jentzen, Daniel Jeromin, et al.
Cancers|September 9, 2023
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/BevacizumabMatthias Jeschke, Johannes M Ludwig, Catherine Leyh, et al.
Pageof 73

Showing results (371-380 of 721) with videos related to

Sort By:
Pageof 73
International Journal of Colorectal Disease|December 4, 2008
The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CTRobert Rosenberg, Ken Herrmann, Ralf Gertler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 19, 2011
Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatmentKen Herrmann, Andreas K Buck, Tibor Schuster, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2011
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinibMatthias R Benz, Ken Herrmann, Franziska Walter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 27, 2025
Multitracer comparison of gold standard PSMA-PET/CT with <sup>68</sup>Ga-FAPI and <sup>18</sup>F-FDG in high-risk prostate cancer: a proof-of-concept studyOsama Mahmoud, Lukas Püllen, Lale Umutlu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 31, 2019
<sup>18</sup>F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue SarcomasJohannes Grueneisen, Benedikt Schaarschmidt, Aydin Demircioglu, et al.
Journal for Immunotherapy of Cancer|October 19, 2023
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapyAnalena Handke, Claudia Kesch, Wolfgang Peter Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 15, 2021
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of diseaseFrancesco Barbato, Wolfgang Peter Fendler, Isabel Rauscher, et al.
Journal for Immunotherapy of Cancer|April 1, 2021
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapyJustin Ferdinandus, Martin Metzenmacher, Lukas Kessler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2022
Lesion Quantification Accuracy of Digital <sup>90</sup>Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide TherapyDavid Kersting, Walter Jentzen, Daniel Jeromin, et al.
Cancers|September 9, 2023
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/BevacizumabMatthias Jeschke, Johannes M Ludwig, Catherine Leyh, et al.
Pageof 73